Literature DB >> 9885544

Outcome in Hodgkin's disease: a 20-year cohort of patients.

L Ranaghan1, G M Markey, T C Morris.   

Abstract

We reviewed the long-term survival, treatment-related mortality and morbidity of a continuous cohort of patients with Hodgkin's disease diagnosed and staged at the Haematology unit of the Belfast City Hospital between January 1973 and October 1992. The analysis included a comparison of the survival of those patients who were entered into BNLI (British National Lymphoma Investigation) trials compared to those not entered during this 20 year period. In addition univariate and multivariate analysis of prognostic factors was performed. The complete remission rate (CR) was 79.6% with a 15 year survival of 55.3%. On multivariate analysis in which deaths due to active Hodgkin's disease only were considered age > 50 emerged as the most significant prognostic factor (P < 0.0007), the presence of B symptoms also having independent significance (P = 0.008). Trial status did not have any independent prognostic significance. Eighty one deaths occurred: active Hodgkin's disease (50), second malignancy (9), treatment-related (10), unrelated (9), unknown (3). This long-term follow up study provides useful information additional to the data produced by clinical trials which are biased by selection criteria. The occurrence of Haemophilus Influenzae meningitis in a patient 17 years following splenectomy highlights the need for appropriate vaccination of patients splenectomised for Hodgkin's disease.

Entities:  

Mesh:

Year:  1998        PMID: 9885544      PMCID: PMC2448989     

Source DB:  PubMed          Journal:  Ulster Med J        ISSN: 0041-6193


  22 in total

1.  SERUM COPPER IN HODGKIN'S DISEASE.

Authors:  K B JENSEN; E B THORLING; C J ANDERSEN
Journal:  Scand J Haematol       Date:  1964

2.  Analysis of trace elements in human tissues. II. The lymphomatous diseases.

Authors:  H J KOCH; E R SMITH; J MCNEELY
Journal:  Cancer       Date:  1957 Jan-Feb       Impact factor: 6.860

3.  Survival outcome after Hodgkin's disease: a report from the international data base on Hodgkin's disease.

Authors:  M Henry-Amar; R Somers
Journal:  Semin Oncol       Date:  1990-12       Impact factor: 4.929

4.  Successful treatment of refractory Hodgkin's disease by high-dose combination chemotherapy and autologous bone marrow transplantation.

Authors:  J G Gribben; D C Linch; C R Singer; A K McMillan; M Jarrett; A H Goldstone
Journal:  Blood       Date:  1989-01       Impact factor: 22.113

5.  Review of British National Lymphoma Investigation studies of Hodgkin's disease and development of prognostic index.

Authors:  J L Haybittle; F G Hayhoe; M J Easterling; A M Jelliffe; M H Bennett; G Vaughan Hudson; B Vaughan Hudson; K A MacLennan
Journal:  Lancet       Date:  1985-04-27       Impact factor: 79.321

6.  LOPP alternating with EVAP is superior to LOPP alone in the initial treatment of advanced Hodgkin's disease: results of a British National Lymphoma Investigation trial.

Authors:  B W Hancock; G Vaughan Hudson; B Vaughan Hudson; M H Bennett; K A MacLennan; J L Haybittle; L Anderson; D C Linch
Journal:  J Clin Oncol       Date:  1992-08       Impact factor: 44.544

7.  Do treatment protocols improve end results? A study of survival of patients with multiple myeloma in Finland.

Authors:  S Karjalainen; I Palva
Journal:  BMJ       Date:  1989-10-28

8.  Hodgkin's disease: summary of twenty years' experience.

Authors:  P Mazza; M Bocchia; P L Zinzani; M Fiacchini; F Gherlinzoni; G Bandini; M Bendandi; G P Frezza; S Neri; E Barbieri
Journal:  Haematologica       Date:  1992 Nov-Dec       Impact factor: 9.941

9.  Hodgkin's disease in northern Sweden 1971-1981. II. A retrospective analysis of prognostic factors.

Authors:  B Norberg; U Dige; G Roos; H Johansson; P Lenner
Journal:  Acta Oncol       Date:  1991       Impact factor: 4.089

10.  British National Lymphoma Investigation randomised study of MOPP (mustine, Oncovin, procarbazine, prednisolone) against LOPP (Leukeran substituted for mustine) in advanced Hodgkin's disease--long term results.

Authors:  B W Hancock; G Vaughan Hudson; B Vaughan Hudson; J L Haybittle; M H Bennett; K A MacLennan; A M Jelliffe
Journal:  Br J Cancer       Date:  1991-04       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.